Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

Fig. 5

Radotinib/Ara-C induces G0/G1 phase cell cycle arrest by regulating the CDKI–CDK–cyclin cascade in HL60, HEL92.1.7 and THP-1 cells. a Cell cycle distribution at 48 h after radotinib/Ara-C treatment. b The expression of CDK2 and cyclin E after radotinib/Ara-C treatment. c The expression of CDK inhibitors such as p21 and p27 by western blot analysis following radotinib/Ara-C treatment. d, e HL60 cells were also collected and treated under the same conditions described in Fig. 4f and g. Cells were analyzed by immunoblotting using an anti-p21 mAb and an anti-p27 mAb. The experiments were repeated three times and the data show representative results. β-Actin was used to confirm equal loading. The results are representative of three independent experiments. R, radotinib; A, Ara-C; R + A, combination of radotinib and Ara-C; BA, bongkrekic acid

Back to article page